The U.K. Prescriptions Medicine Code of Practice Authority ruled that GlaxoSmithKline violated its code of conduct in promotions for Revolade, a drug to treat the bleeding disorder immune thrombocytopenic purpura. A Glaxo employee told the association that a Glaxo sales rep had promoted Revolade for myeloid fibrosis to a consultant with the National Health Service through meetings and e-mails, which, the panel ruled, contained confusing language written by the marketing department.

Related Summaries